Novo Nordisk's August Reckoning: Trial Data, EU Approval, and a Split Analyst Camp

Novo Nordisk wraps ZEUS trial, wins EU approval for oral Wegovy, and launches US employer access deal, with analysts split on 2029 outlook.

The Danish pharmaceutical giant finds itself at an unusual crossroads as the calendar flips toward early August. On one side sits a freshly completed Phase-3 cardiovascular trial that could reshape the company's growth narrative; on the other, a newly approved oral obesity treatment in Europe and a novel US employer-access deal that has analysts sharply divided over what it all means for the bottom line.

The stock itself has been a study in muted response. After closing Thursday at EUR 44.66, down 1.01 percent, shares slipped another 1.28 percent on Friday to EUR 44.09. Those modest daily moves belie the scale of what is unfolding beneath the surface.

ZEUS Wraps Up, Opening a Potential Second Growth Pillar

Novo Nordisk has officially closed the books on ZEUS, its Phase-3 trial evaluating ziltivekimab, an interleukin-6 inhibitor. The study tracked 6,376 patients suffering from calcified heart vessels, chronic kidney disease, and systemic inflammation. With the follow-up period now complete, the company has moved into the data-analysis phase.

The significance extends well beyond the cardiology indication itself. Analysts view a successful readout as the key to diversifying a revenue base that remains heavily dependent on Ozempic and Wegovy. A foothold in cardiovascular medicine would give the company a second engine of growth — and reduce its exposure to the intensifying competitive pressure in the GLP-1 weight-loss market.

EU Green Light and a US Access Experiment

The European Commission has approved the once-daily oral Wegovy tablet for obesity across all member states, marking the first authorization of its kind for an oral GLP-1 therapy in Europe. The timing is notable: it lands alongside a partnership with US-based Crux, announced in July, designed to streamline access to Novo Nordisk's weight-loss medications through employer-sponsored health plans.

The Crux arrangement operates through an alternative reimbursement structure. Companies can offer access to Novo Nordisk products via a licensed NovoCare network pharmacy, with transparent, predictable pricing for both employers and employees. Funding flows through tax-advantaged health savings accounts. Tom Scales, the company's senior vice president for market access, frames the deal as one component of a broader access strategy — one that also includes telehealth and direct-distribution partnerships launched this year as the company defends its US market share against pricing pressure and a wave of oral competitors.

The Analyst Divide: A 50-Billion-Krone Gap

Wall Street's reaction to these parallel developments has been anything but uniform. The divergence is starkest in 2029 projections, where the gap between bear and bull cases has grown cavernous.

The most pessimistic forecasters see revenue of roughly DKK 274 billion and profit of about DKK 79.6 billion by 2029. Their concerns center on Wegovy's growth trajectory and pricing power, which they argue face mounting threats from oral GLP-1 rivals and regulatory uncertainty surrounding access models like the Crux deal.

The optimists paint a markedly different picture: DKK 325.6 billion in revenue and DKK 102.6 billion in profit. That roughly DKK 50 billion revenue spread — and a 23 billion kroner profit gap — underscores just how little consensus exists about the company's medium-term prospects.

Institutional Moves and the Chart Picture

While analysts argue, some institutional investors have been voting with their wallets. Waverly Advisors LLC expanded its position by a striking 396.5 percent during the first quarter. The Royal Bank of Canada added a more modest 3.2 percent, bringing its holdings to approximately 4.5 million shares.

These moves arrive days before a pivotal moment: Novo Nordisk reports first-half 2026 results on August 5. The market will be watching how the company balances heavy capital expenditure on new production capacity against the strong cash flow generated by its existing portfolio. The earnings release should also offer initial commentary on the cardiovascular pipeline.

The share price has clawed back ground from its March lows, when the stock touched EUR 30.25. Over the past seven trading days, shares have gained 4.15 percent, though year-to-date appreciation stands at a more modest 1.45 percent. The stock remains 18.58 percent below its 52-week high of EUR 54.86, set on January 23, 2026 — a slightly narrower gap than the 19.62 percent deficit measured from the January peak of EUR 54.86 in the other data set. Market capitalization currently sits at approximately EUR 197.43 billion.

Whether the ZEUS milestone, the EU approval, and the Crux partnership can collectively offset the competitive headwinds is the question hanging over the August 5 report. For now, the range of analyst estimates suggests the market itself has yet to settle on an answer.